A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI).
Epistemonikos ID: 56ea11904bacaccfbecba363605f16a115e828bc
First added on: May 11, 2024